In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Get the (GTOP) Report Here
Trade with Jim Cramer 14 Days FREE
Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.
Cell Genesys' 'news' this week doesn't do much to boost prospects for its prostate cancer vaccine.
Medarex's recent drop in stock price means the FDA isn't likely to approve its melanoma drug soon.
Chordiant inks a big deal with a telecom company.
ValueClick and NetSuite could move higher.
Failing a phase III trial is never a good thing. Don't believe a CEO's attempt to spin it otherwise.
RIMM benefited from the explosive demand for Blackberry's.
The stock gets crushed after the drug can't meet its endpoint.
It's still too early to be a Pain Therapeutics bull.
Study results expected in December offer a big risk/reward scenario.
Here's a list of stocks set to report phase III trial results.
This week, questions on Genitope, Immunogen and Nymox. Plus, is Adam really that negative?
The biotech outfit loses nearly half its market cap after saying a trial of MyVax might run until December 2007.
Hologic moves higher after raising sales projections for its digital-mammography systems.
The drugmaker has uncommonly strong finances for a biotech company and trades at a discount.
S&P 500 companies are flush with cash, as are LBO firms, and they're going to put their money to work.
Stamina is key to consistent results, so new traders, lose that rigid, time-consuming routine.
The shares are down nearly 30% after a data board recommends continuing a lymphoma trial.
The company's waiting on a response from one board before taking its cancer vaccine to the FDA. Here's one analyst's guide.
The aftermarket success of Dutch auction IPOs underscores the value of the process to the Googles and micro-caps of the world.
The selling in this name has been largely irrational. Cooler heads say it's time to buy.
Fourth quarter set to be most active in a year but flood of biotech issues brings weak results.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.